Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma

Recently, immunotherapy based on blocking immune checkpoints with programmed death‐1 (PD‐1) or PD‐ligand 1 (PD‐L1) Abs has been introduced for the treatment of advanced clear cell renal cell carcinoma (ccRCC), especially tumors resistant to vascular endothelial growth factor‐tyrosine kinase inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikami, Shuji, Mizuno, Ryuichi, Kondo, Tsunenori, Shinohara, Nobuo, Nonomura, Norio, Ozono, Seiichiro, Eto, Masatoshi, Tatsugami, Katsunori, Takayama, Tatsuya, Matsuyama, Hideyasu, Kishida, Takeshi, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550131/
https://www.ncbi.nlm.nih.gov/pubmed/30972888
http://dx.doi.org/10.1111/cas.14019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550131/
https://www.ncbi.nlm.nih.gov/pubmed/30972888
http://dx.doi.org/10.1111/cas.14019

Ejemplares similares